Regeneron Pharmaceuticals Inc. (REGN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Regeneron Pharmaceuticals...

    NASDAQ: REGN · Real-Time Price · USD
    571.56
    4.34 (0.77%)
    At close: Sep 05, 2025, 3:08 PM

    Regeneron Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 14.2B 13.12B 12.17B 16.07B
    Cost of Revenue
    		 2.45B 2.24B 1.71B 2.72B
    Gross Profit
    		 11.75B 10.87B 10.47B 13.35B
    Operating Income
    		 4.17B 4.35B 5.39B 8.95B
    Interest Income
    		 711.4M 495.9M 160.1M n/a
    Pretax Income
    		 4.78B 4.2B 4.86B 9.33B
    Net Income
    		 4.41B 3.95B 4.34B 8.08B
    Selling & General & Admin
    		 2.9B 2.54B 2.12B 1.82B
    Research & Development
    		 4.62B 3.99B 3.06B 2.62B
    Other Expenses
    		 53.4M -2.1M -89.9M -45.6M
    Operating Expenses
    		 7.58B 6.52B 5.08B 4.4B
    Interest Expense
    		 55.2M 73M 59.4M 57.3M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 10.03B 8.77B 6.79B 7.12B
    Income Tax Expense
    		 367.3M 245.7M 520.4M 1.25B
    Shares Outstanding (Basic)
    		 107.9M 106.7M 107.1M 105.7M
    Shares Outstanding (Diluted)
    		 115.1M 113.7M 113.5M 112.2M
    EPS (Basic)
    		 40.90 37.05 40.51 76.40
    EPS (Diluted)
    		 38.34 34.77 38.22 71.97
    EBITDA
    		 5.32B 4.69B 5.26B 9.67B
    EBIT
    		 4.84B 4.27B 4.92B 9.38B
    Depreciation & Amortization
    		 482.9M 421M 341.4M 286.2M

    Add to Watchlist